top of page
News, Events and Updates
Search
Anavex Scales Up Synthesis of ANAVEX 2-73 for Phase 1 Alzheimer’s Disease Study
Jan 30, 2009
Ground-Breaking Anti-Amnesic and Neuroprotective Effects of Alzheimer’s Compound ANAVEX 1-41
Dec 17, 2008
Anavex Presents Potent Neuroprotective Effects of ANAVEX 1-41 at Neuroscience 2008
Dec 4, 2008
Anavex Completes Successful Preclinical Studies on Lead Alzheimer’s Drug Candidate
Sep 1, 2008
Anavex Presents Neuroprotective Effects of ANAVEX 1-41 at the International Conference on AD 2008
Jul 29, 2008
Anavex Life Sciences Corp. Will Present New Findings at the International Conference on AD 2008
Jun 23, 2008
Anavex Further Strengthens Board of Directors
Jun 2, 2008
Anavex Announces Appointment of Oncology Specialist to Board of Directors
May 20, 2008
Low density of sigma-1 receptors in early Alzheimer’s disease.
Apr 9, 2008
ANAVEX 7-1037 Reduces Rate of Cancer Tumor Growth 69% in Pre-Clinical Studies, Compared to Currently
Mar 9, 2008
Anavex Outlines Corporate Milestones, Drug Advancement Plans for 2008
Jan 22, 2008
48
49
50
51
52
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
